mersenneforum.org  

Go Back   mersenneforum.org > Fun Stuff > Lounge

Reply
 
Thread Tools
Old 2022-01-23, 20:38   #1651
Batalov
 
Batalov's Avatar
 
"Serge"
Mar 2008
Phi(4,2^7658614+1)/2

227378 Posts
Default

Soon someone will repost it everywhere and even add: "A Doctor reported: ..."

LABELED SATIRE!
Batalov is offline   Reply With Quote
Old 2022-01-23, 22:47   #1652
a1call
 
a1call's Avatar
 
"Rashid Naimi"
Oct 2015
Remote to Here/There

2,207 Posts
Default

They’re only Alternative-Facts. It is still alternatively factual. It’s all good.
The actual goings on in Florida is not far from it.
a1call is offline   Reply With Quote
Old 2022-01-25, 21:26   #1653
Dr Sardonicus
 
Dr Sardonicus's Avatar
 
Feb 2017
Nowhere

22·17·79 Posts
Default

Lab tests: Eli Lilly, Regeneron antibody therapies lose out against Omicron
Quote:
FRANKFURT, Dec 14 (Reuters) - German researchers have found that COVID-19 therapies developed by Eli Lilly (LLY.N) and Regeneron (REGN.O) lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of coronavirus, likely reducing treatment options if the new variant prevails.
<snip>
The findings have not yet been peer-reviewed for publication in a medical journal.
<snip>
Asked about the antibody findings, Ely Lilly said it expected the efficacy of its antibody combination to be lower.

"Due to the substitutions contained within the spike protein of the Omicron variant of concern, it appears that bamlanivimab with etesevimab is likely to experience reduced neutralization activity," said a spokesperson.

The company was conducting its own Omicron tests, also including its experimental antibody bebtelovimab, and would report the initial findings as soon as possible.

Regeneron, which last month cited tests suggesting its drug would have reduced efficacy against the Omicron variant, said on Tuesday that it expected to share more information from further analyses soon.
<snip>
Prevention
Quote:
Dec 22, 2021

Why don't some monoclonal antibody treatments work well against Omicron?

A lot of it comes down to the way that these monoclonal antibody treatments were designed, says Thomas Russo, M.D., professor and chief of infectious disease at the University at Buffalo in New York. "The Eli Lilly and Regeneron monoclonal antibody treatments are directed against the spike protein of SARS-CoV-2, and Omicron has 32 mutations and a deletion in the spike protein," he says. "Because of this, those treatments no longer bind with the virus."

As a result, "it is not expected that these products will have any meaningful effect on those with the Omicron variant," says infectious disease expert Amesh A. Adalja, M.D., a senior scholar at the Johns Hopkins Center for Health Security.
So it is absolutely no surprise that the FDA limited its EUA's:
Quote:
For Immediate Release:
January 24, 2022
Statement From: Patrizia Cavazzoni, M.D.
Director - Center for Drug Evaluation and Research

In light of the most recent information and data available, today, the FDA revised the authorizations for two monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab) – to limit their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible to these treatments.
Apparently Florida Governor DeSantis cares more about politics: DeSantis blasts halt in antibody treatments even as drugmakers say they don't work on omicron
Quote:
Gov. Ron DeSantis slammed the Biden administration Tuesday for dropping two antibody treatments for COVID-19 that he has championed, even though the drugmakers themselves concede they are ineffective against omicron.

Monoclonal antibodies from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant that now accounts for nearly all U.S. infections, federal regulators said Monday night.
<snip>
DeSantis claimed the Food and Drug Administration's decision was made based on "a single, non-peer reviewed, non-clinical study that was actually done by a consultant for a rival company to the other two monoclonal antibody treatments. ... It's really a reckless decision to be able to take this option away from patients."

Asked why DeSantis did not accept the drug companies' own conclusions that the drugs are ineffective, the governor's spokeswoman Christina Pushaw didn’t answer the question and instead pointed to the study DeSantis referenced in his remarks.
<snip>
Thomas Unnasch, a distinguished professor at the University of South Florida's College of Public Health, said it would be unethical to continue administering these drugs despite evidence they don’t work on the majority of cases.
<snip>
DeSantis argued for the drugs' continued use even despite their decreased effectiveness. "Even if with Omicron, it's half as effective or even 25% as effective, that's better than nothing for people," DeSantis said.

But Unnasch disagreed.

"The laboratory results that are out there ... make it abundantly clear that they don't work at all," Unnasch said. "They're not 50% successful. They are more than 99.99% ineffective."
<snip>
Regeneron announced in November that studies showed its antibody drug cocktail lost effectiveness against omicron, while Eli Lilly made a similar announcement about its treatment in December.

Both Eli Lilly and Regeneron also issued statements Monday and Tuesday agreeing with the FDA's decision.
<snip>

Last fiddled with by Dr Sardonicus on 2022-01-25 at 21:28 Reason: eliminate extraneous newlines
Dr Sardonicus is offline   Reply With Quote
Reply

Thread Tools


All times are UTC. The time now is 23:01.


Tue Jan 25 23:01:54 UTC 2022 up 186 days, 17:30, 0 users, load averages: 1.46, 1.46, 1.44

Powered by vBulletin® Version 3.8.11
Copyright ©2000 - 2022, Jelsoft Enterprises Ltd.

This forum has received and complied with 0 (zero) government requests for information.

Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation.
A copy of the license is included in the FAQ.

≠ ± ∓ ÷ × · − √ ‰ ⊗ ⊕ ⊖ ⊘ ⊙ ≤ ≥ ≦ ≧ ≨ ≩ ≺ ≻ ≼ ≽ ⊏ ⊐ ⊑ ⊒ ² ³ °
∠ ∟ ° ≅ ~ ‖ ⟂ ⫛
≡ ≜ ≈ ∝ ∞ ≪ ≫ ⌊⌋ ⌈⌉ ∘ ∏ ∐ ∑ ∧ ∨ ∩ ∪ ⨀ ⊕ ⊗ 𝖕 𝖖 𝖗 ⊲ ⊳
∅ ∖ ∁ ↦ ↣ ∩ ∪ ⊆ ⊂ ⊄ ⊊ ⊇ ⊃ ⊅ ⊋ ⊖ ∈ ∉ ∋ ∌ ℕ ℤ ℚ ℝ ℂ ℵ ℶ ℷ ℸ 𝓟
¬ ∨ ∧ ⊕ → ← ⇒ ⇐ ⇔ ∀ ∃ ∄ ∴ ∵ ⊤ ⊥ ⊢ ⊨ ⫤ ⊣ … ⋯ ⋮ ⋰ ⋱
∫ ∬ ∭ ∮ ∯ ∰ ∇ ∆ δ ∂ ℱ ℒ ℓ
𝛢𝛼 𝛣𝛽 𝛤𝛾 𝛥𝛿 𝛦𝜀𝜖 𝛧𝜁 𝛨𝜂 𝛩𝜃𝜗 𝛪𝜄 𝛫𝜅 𝛬𝜆 𝛭𝜇 𝛮𝜈 𝛯𝜉 𝛰𝜊 𝛱𝜋 𝛲𝜌 𝛴𝜎 𝛵𝜏 𝛶𝜐 𝛷𝜙𝜑 𝛸𝜒 𝛹𝜓 𝛺𝜔